A Study of LY3437943 in Postmenopausal Female Participants Who Are Overweight or Obese
Completed · Phase 1 · NCT06039826
Conditions: Overweight
At a glance
- Research payments reported, 2025
- $5,436
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 46
About the trial
- Sponsor
- Eli Lilly and Company
- Tested
- LY3437943 (drug), Ethinyl Estradiol (drug), Drospirenone (drug)
- Dates
- Started 2023-09-12; completion 2024-07-11
- Results posted
- Not yet
The main purpose of this study is to determine the effect of LY3437943 when administered subcutaneously on the levels of combined oral contraceptive (COC) ethinyl estradiol and drospirenone in the blood stream in postmenopausal female participants who are overweight or obese. The safety and tolerability of LY3437943 when administered with COC will also be evaluated. This study will last up to approximately 29 weeks for each participant.
From ClinicalTrials.gov, last updated 2024-07-26. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Eli Lilly and Company reported $5,436 in research payments for this study in 2025 (1 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Qps-Mra LLC $5,436
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.